Servier steps out of home base to get products made in India

French pharmaceutical group Servier is stepping out of its home base for the first time in over 70 years to get its products made abroad, for other export markets.

Governed by a foundation, Servier has set up a global platform in India — ‘Gatinn’ — to work with local companies and develop, manufacture and export Single Pill Combinations (SPCs) for cardiometabolic and venous diseases. The company will invest about €15 million in 2026 in this platform.

The company will import active ingredients of the products from its plants in France, and work with manufacturing partners in India to turn those ingredients into finished tablets and ultimately into packaging, Bradley Lloyd, Managing Director, Servier (APAC region), told businessline. The company will export from India to markets in South America, South Asia, West Asia and possibly Africa, he said, adding, “this will be the first time in the group’s history that we will export from India at scale to other markets.”

Servier will partner with two contract development and manufacturing organisations (CDMO), said Aurelien Breton, Managing Director, Servier India. The investment will be in establishing the Gatinn team, besides undertaking bioequivalencies, Phase-III studies and development of products, he said.

Challenging times

The recent European Union-India trade deal brings in intellectual property protection that perhaps will create even more favourable conditions, said Lloyd. Breton said Servier was poised to launch its third oncology product Voranigo, for brain cancer, next month. The product was approved in India weeks after Europe.

On keeping innovative products affordable, Lloyd said, “It’s a very difficult topic...because we’re operating today in a very uncertain world with the most favoured nation policy of the US government. It’s creating a lot of uncertainty when it comes to pricing of pharmaceutical innovation and it creates a lot of challenge for us as to how can we navigate through these uncertain times, being sure that we protect the interests of patients and protect the interests of our group, and today this is proving to be rather challenging.”

Breton added that they would start with the international price, and have a patient assistance programme.

Gatinn platform

Charlotte Marmousez, Executive Vice-President - Corporate Strategy & Transformation, saidthis is Servier’s first platform which will coordinate on behalf of the global Servier teams from research and manufacturing, based in the headquarters in France. Few projects have already been initiated with the first international launch expected in Q2-2027. The platform is expected to have around five products in development by 2026-end, followed by the addition of approximately one new SPC each year till 2030.

Dr Kshitij Panse, Chief Operating Officer - GATINN, said,by combining a local team, carefully selected partners and Servier’s global R&D, manufacturing and quality expertise, the platform will execute high-quality SPCs that meet global standards and help improve adherence and outcomes for patients worldwide.

Published on February 10, 2026